Risk of Malignancy in TR5 Thyroid Nodules
A TR5 (highly suspicious) thyroid nodule carries at least a 20% risk of malignancy according to ACR TI-RADS guidelines, though recent real-world data suggests the actual malignancy rate ranges from 12-64% depending on nodule characteristics and institutional practices. 1
Understanding the TR5 Classification
TR5 nodules are assigned 7 or more points on the ACR TI-RADS scoring system based on suspicious ultrasound features including:
- Very hypoechoic appearance (2-3 points)
- Taller-than-wide shape (3 points)
- Irregular or lobulated margins (2-3 points)
- Punctate echogenic foci/microcalcifications (3 points)
- Solid composition (2 points)
Actual Malignancy Rates from Recent Studies
The malignancy risk varies considerably across recent institutional studies:
- 40.7% malignancy rate in a large Canadian series of 1,140 nodules 2
- 21.1% malignancy rate in a U.S. single-institution study of 450 TR5 nodules 3
- 12.3% malignancy rate in another U.S. integrated health system study of 496 TR5 nodules 4
- 64.4% malignancy rate specifically in TR5 nodules <10 mm that underwent surgery 5
The wide variation (12-64%) reflects differences in patient selection, institutional biopsy practices, and whether surgical pathology or cytology was used as the gold standard. Studies using only surgical pathology show higher rates because they exclude benign nodules that were not operated on.
Key Predictive Features Within TR5
Not all TR5 nodules carry equal risk. Higher total TI-RADS points within the TR5 category correlate with increased malignancy risk (average 9.3 points in malignant vs 7.3 points in benign TR5 nodules). 4
Specific features with highest predictive value:
- Very hypoechoic appearance: 95.5% specificity, 44.8% positive predictive value 3
- Suspected extrathyroidal extension: Odds ratio 27.2 for malignancy 2
- Punctate echogenic foci: Odds ratio 11 for malignancy (but only 20% positive predictive value) 2, 3
Clinical Management Algorithm
For TR5 nodules ≥1 cm: Proceed with fine needle aspiration (FNA) 1
For TR5 nodules 5-9 mm: The ACR TI-RADS white paper acknowledges controversy regarding papillary microcarcinomas in this size range. Recent data shows 64.4% malignancy rate in TR5 nodules <10 mm that underwent surgery, supporting consideration of FNA in selected cases when active surveillance is unsuitable. 1, 5
For TR5 nodules <5 mm: Follow-up ultrasound at 0.5 cm threshold rather than immediate FNA, given the indolent nature of most papillary microcarcinomas 1
Important Caveats
Age significantly modifies risk: Younger patients with TR5 nodules have higher malignancy rates, with odds of malignancy consistently decreasing with advancing age across all TI-RADS categories. 2, 6
Beware of scoring inconsistencies: Benign TR5 nodules more frequently received points when radiologists were "unable to determine composition or echogenicity" (33% vs 3% in malignant nodules), suggesting potential for quality improvement in ultrasound reporting. 4
The 20% threshold is a minimum: The ACR TI-RADS committee designed the system to identify nodules with "at least 20%" malignancy risk, not an exact rate. The actual risk for any individual TR5 nodule depends on the specific constellation of features present. 1